BERKELEY, CA (UroToday.com) - June 21, 2012 - Translating the clinical results observed from pre-specified interim analyses of the randomized, placebo-controlled phase III study, COU-AA-302 demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS), and all secondary endpoints, compared to patients treated with placebo plus prednisone.
To read more, a FREE Urotoday registration is required. Click here to register or login above.To read UIJ content, a separate subscription is required.
Tags: